Technical Analysis for SNPX - Synaptogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Flat | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 20 DMA | Bullish | -1.05% | |
Crossed Above 50 DMA | Bullish | -1.05% | |
MACD Bullish Signal Line Cross | Bullish | -1.05% | |
Bollinger Band Squeeze | Range Contraction | -1.05% |
Alert | Time |
---|---|
20 DMA Support | about 11 hours ago |
10 DMA Support | about 11 hours ago |
50 DMA Support | about 11 hours ago |
Rose Above Upper Bollinger Band | about 11 hours ago |
1.5x Volume Pace | about 11 hours ago |
Get a Trading Assistant
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Stroke Multiple Sclerosis Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 47.0 |
52 Week Low | 3.5275 |
Average Volume | 52,664 |
200-Day Moving Average | 7.24 |
50-Day Moving Average | 4.69 |
20-Day Moving Average | 4.63 |
10-Day Moving Average | 4.72 |
Average True Range | 0.46 |
RSI (14) | 51.46 |
ADX | 28.94 |
+DI | 23.35 |
-DI | 12.17 |
Chandelier Exit (Long, 3 ATRs) | 4.00 |
Chandelier Exit (Short, 3 ATRs) | 5.58 |
Upper Bollinger Bands | 4.98 |
Lower Bollinger Band | 4.28 |
Percent B (%b) | 0.62 |
BandWidth | 14.92 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.007 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.60 | ||||
Resistance 3 (R3) | 5.62 | 5.36 | 5.45 | ||
Resistance 2 (R2) | 5.36 | 5.13 | 5.34 | 5.40 | |
Resistance 1 (R1) | 5.03 | 4.99 | 5.20 | 5.01 | 5.35 |
Pivot Point | 4.77 | 4.77 | 4.85 | 4.75 | 4.77 |
Support 1 (S1) | 4.44 | 4.54 | 4.61 | 4.42 | 4.07 |
Support 2 (S2) | 4.18 | 4.40 | 4.16 | 4.02 | |
Support 3 (S3) | 3.85 | 4.18 | 3.97 | ||
Support 4 (S4) | 3.83 |